EVALUATION STUDIES
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Discovery of new analogs of the marine biotoxin azaspiracid in blue mussels (Mytilus edulis) by ultra-performance liquid chromatography/tandem mass spectrometry.

Azaspiracids (AZAs) are a group of lipophilic marine biotoxins that were first discovered in blue mussels harvested in 1995 in Killary Harbour on the west coast of Ireland. At least eight people fell ill after the consumption of contaminated mussels and developed symptoms of nausea, stomach cramps, vomiting and severe diarrhoea. Until now, eleven different analogs of these toxins have been described, with a twelfth one theoretically postulated. This paper describes the detection and identification of twenty new analogs of azaspiracid, including dihydroxy-AZAs and carboxy-AZAs, using state-of-the-art techniques including ultra-performance liquid chromatography (UPLC) and tandem mass spectrometry (MS/MS). Blue mussels (Mytilus edulis) from a toxic event of the northwest coast of Ireland in 2005 were extracted and analysed using LC/MS. The mass spectra obtained from different instruments enabled identification of previously unknown analogs of azaspiracid with additional hydroxyl and carboxyl substituents. Mass fragmentation patterns of the dihydroxy-AZAs indicated the positions of these substituents to be at the C3 and C23 position. The previously theoretically postulated AZA12 was also observed in this study. Product ion spectra showed the presence of a unique fragment ion at m/z 408 for all C23-hydroxylated analogs. This fragmentation competes with the fragmentation leading to m/z 362, a fragment ion that has shown to be present in all AZAs. The novel analogs have not been seen in plankton or water samples and are believed to be metabolites of AZAs formed in mussels. All the new AZA analogs were present at low concentrations in the shellfish and it is probably safe to assume that they do not pose a risk for the shellfish consumer.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app